Trials / Completed
CompletedNCT01919398
A Study of LY2940680 in Japanese Participants With Advanced Cancers
A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940680 | Administered orally |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-05-01
- Completion
- 2017-06-28
- First posted
- 2013-08-09
- Last updated
- 2019-09-11
- Results posted
- 2019-09-11
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01919398. Inclusion in this directory is not an endorsement.